Search company, investor...

Pilz Bioscience


Acquired | Acquired

About Pilz Bioscience

Pilz Bioscience is a biotechnology company that develops medicinal psychedelics for neuroinflammatory conditions with a significant cognitive component and high unmet needs, with a focus on Autism Spectrum Disorder (ASD). On November 30, 2020 Pilz Bioscience was acquired by Nova Mentis Life Science. The terms of the transaction were not disclosed.

Headquarters Location

Suite 2200-HSBC Building 885 W. Georgia St.

Vancouver, British Columbia, V6C 3E8,


Missing: Pilz Bioscience's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Pilz Bioscience's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Pilz Bioscience

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pilz Bioscience is included in 2 Expert Collections, including Psychedelics.



329 items


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Pilz Bioscience Patents

Pilz Bioscience has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics




Industrial automation, Production and manufacturing, Physical optics, Control engineering, Statistical process control


Application Date


Grant Date



Related Topics

Industrial automation, Production and manufacturing, Physical optics, Control engineering, Statistical process control



Latest Pilz Bioscience News

Nova Mentis to Enter mRNA AI Diagnostics Business

Apr 26, 2023

Vancouver, British Columbia--(Newsfile Corp. - April 26, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce the launch of SwabAi Diagnostics Inc. (SwabAi). The Company intends to unleash the full potential of this technology as a stand-alone business. NOVA's wholly owned subsidiary, Pilz Bioscience Inc., will undergo a name change to SwabAi Diagnostics, Inc. prior to a planned corporate spinout. "NOVA's novel mRNA technology has the potential to assess the neuroinflammatory condition of a patient on initial evaluation and ability to monitor drug treatment response. This genomic technology opens the door for the development of breakthrough products in psychedelic medicine. We believe this technology can be used by the pharmaceutical industry to evaluate efficacy of drugs in the treatment of chronic inflammatory disorders of the central nervous system," stated Will Rascan, NOVA's President & CEO. Using buccal swab samples that are easily collected from patients, SwabAi has developed a proprietary diagnostic panel that examines a 52-mRNA microarray output using machine learning AI to uncover inflammatory gene patterns associated with specific neuroinflammatory conditions. Currently, in the evaluation and treatment of various neurological and psychological diseases, efficacy measurements are largely dependent on patient and professional observer feedback through standardized and accepted questionnaires that have a biased component. NOVA's goal in utilizing its mRNA biomarker panel technology is to assess the physiological changes that may be occurring in a patient throughout the course of treatment. This information will provide practitioners with an additional layer of objective data points from which to base drug dosages as well as response to treatment. "This technology has far-reaching implications and merits over and above its utilization in our current Health Canada approved Phase IIA fragile X syndrome clinical studies," said Derek Ivany, NOVA's Executive Chairman. "SwabAi plans to assess potential synergistic corporate development opportunities with companies in the neuroscience arena." According to Statista, in 2021, artificial intelligence (AI) in the healthcare market was worth around US$11 billion worldwide. It was forecast that the global healthcare AI market could be worth almost US$188 billion by 2030, increasing at a compound annual growth rate of 37 percent from 2022 to 2030. NOVA believes that its proprietary mRNA diagnostic technology is not realizing its full value nor commercialization potential within the current corporate framework. As such, management and the Board of Directors are considering distributing its ownership of the standalone entity, SwabAi, to NOVA shareholders. Further details such as finalization, timing and the exchange ratio will be determined in due course. Although management believes that this proposal has commercial as well as shareholder value, there is no assurance at this time that the spinout will be enacted. About Nova Mentis Life Science Corp. Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS). NOVA's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS. For further information on the Company, please visit or email . On Behalf of the Board Will Rascan, President & CEO Phone: 778-819-0244 Facebook: @novamentislsc Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur. To view the source version of this press release, please visit Sign up for Alerts Sign up to receive news releases by email for Nova Mentis Life Science Corp. or all companies belonging to the Biotechnology, Health, Technology industries.

Pilz Bioscience Frequently Asked Questions (FAQ)

  • Where is Pilz Bioscience's headquarters?

    Pilz Bioscience's headquarters is located at Suite 2200-HSBC Building, Vancouver.

  • What is Pilz Bioscience's latest funding round?

    Pilz Bioscience's latest funding round is Acquired.

  • Who are the investors of Pilz Bioscience?

    Investors of Pilz Bioscience include Nova Mentis Life Science.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.